Hematogenix Laboratory Services, LLC Announces the Availability of FDA Approved PD-L1 Companion Diagnostic Tests
Hematogenix Laboratory Services Announces the Availability of PD-L1 Companion Diagnostic Tests for KEYTRUDA®, Merck's Anti-PD-1 Therapy for Metastatic Non-Small Cell Lung Cancer Whose Tumors Express PD-L1 with Disease Progression on or after Platinum-Containing Chemotherapy as well as a PD-L1 Complementary Diagnostic Test to Support Bristol-Myers Squibb's OPDIVO® Anti-PD-1 Therapy for Non-Squamous Non-Small Cell Lung Cancer. - March 24, 2016
Hematogenix Laboratory Services to Offer FDA Approved THxID®‐BRAF Companion Diagnostic Testing Services in the US
Hematogenix® is among the first CLIA (Clinical Laboratory Improvement Amendments) facilities to offer the test to detect two BRAF mutations, V600E and V600K. - February 11, 2014
Press Releases 1 - 2 of 2